logo
logo

Circle Pharma Strengthens Its Executive Leadership Team With Two Senior Appointments In Clinical Development

Circle Pharma Strengthens Its Executive Leadership Team With Two Senior Appointments In Clinical Development

07/26/23, 12:11 PM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgsan francisco
Industry
healthcare
Circle Pharma, a biopharmaceutical company advancing the discovery and development of intrinsically cell-permeable macrocycles, announced today the appointments of Michael Cox, PharmD., MHSc, BCOP as senior vice president, head of Early Development, and Edward Garmey, M.D., as its new consulting chief medical officer. These additions to the leadership team further bolster Circle Pharma's capabilities in oncology drug development as it advances its Cyclin A/B inhibitor program into clinical studies. In addition to Dr. Cox's appointment, Circle Pharma is pleased to welcome Edward Garmey, M.D., as the new consulting Chief Medical Officer

Company Info

Company
Circle Pharma
Location
681 gateway blvd
san francisco, california, united states
Additional Info
Circle Pharma initiated operations in June 2014 with seed funding from Pfizer, Inc. and Mission Bay Capital, LLP; we received additional seed funding from ShangPharma Investment Group Limited in November 2015. We recently raised Series B and Series C financing from The Column Group and NextTech Invest. We design and develop bioavailable macrocyclic peptide therapeutics against important clinical targets. We do this by applying a computational structure-based design approach that combines physics (conformational modeling), chemistry (innovative molecular components) and biology (protein target structure and function). We have selected intracellular protein-protein interactions that play key roles in cancer as the initial target group for our internal pipeline development.

Related People